Citigroup Inc. Has $35000 Stake in MedEquities Realty Trust Inc (MRT)

Acadian Asset Management LLC lifted its stake in shares of MedEquities Realty Trust by 97.4% during the 4th quarter. Acadian Asset Management …

MedEquities Realty Trust logoCitigroup Inc. lessened its holdings in shares of MedEquities Realty Trust Inc (NYSE:MRT) by 54.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,187 shares of the financial services provider’s stock after selling 6,233 shares during the quarter. Citigroup Inc.’s holdings in MedEquities Realty Trust were worth $35,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also modified their holdings of the company. Acadian Asset Management LLC lifted its stake in shares of MedEquities Realty Trust by 97.4% during the 4th quarter. Acadian Asset Management LLC now owns 12,173 shares of the financial services provider’s stock valued at $83,000 after buying an additional 6,005 shares in the last quarter. MetLife Investment Advisors LLC lifted its stake in shares of MedEquities Realty Trust by 65.1% during the 3rd quarter. MetLife Investment Advisors LLC now owns 17,683 shares of the financial services provider’s stock valued at $172,000 after buying an additional 6,974 shares in the last quarter. California Public Employees Retirement System lifted its stake in shares of MedEquities Realty Trust by 56.6% during the 4th quarter. California Public Employees Retirement System now owns 32,442 shares of the financial services provider’s stock valued at $222,000 after buying an additional 11,725 shares in the last quarter. Rhumbline Advisers lifted its stake in shares of MedEquities Realty Trust by 33.5% during the 4th quarter. Rhumbline Advisers now owns 45,088 shares of the financial services provider’s stock valued at $308,000 after buying an additional 11,318 shares in the last quarter. Finally, Strs Ohio lifted its stake in shares of MedEquities Realty Trust by 5.8% during the 4th quarter. Strs Ohio now owns 50,361 shares of the financial services provider’s stock valued at $344,000 after buying an additional 2,748 shares in the last quarter. Institutional investors and hedge funds own 88.20% of the company’s stock.

In other MedEquities Realty Trust news, Director Bluemountain Capital Managemen sold 210,000 shares of MedEquities Realty Trust stock in a transaction on Tuesday, January 15th. The shares were sold at an average price of $10.65, for a total value of $2,236,500.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Over the last quarter, insiders sold 1,364,462 shares of company stock worth $14,862,718. 3.00% of the stock is currently owned by insiders.

Shares of NYSE MRT opened at $10.80 on Thursday. The firm has a market capitalization of $348.65 million, a price-to-earnings ratio of 9.47 and a beta of 1.72. MedEquities Realty Trust Inc has a 52-week low of $6.27 and a 52-week high of $11.85.

A number of research firms recently weighed in on MRT. TheStreet upgraded shares of MedEquities Realty Trust from a “d+” rating to a “c-” rating in a research note on Wednesday, January 16th. ValuEngine downgraded shares of MedEquities Realty Trust from a “buy” rating to a “hold” rating in a report on Wednesday, February 13th. B. Riley reiterated a “neutral” rating and issued a $10.00 price target (down from $10.50) on shares of MedEquities Realty Trust in a report on Thursday, January 3rd. Zacks Investment Research upgraded shares of MedEquities Realty Trust from a “strong sell” rating to a “hold” rating in a report on Tuesday, January 22nd. Finally, Raymond James downgraded shares of MedEquities Realty Trust to a “market perform” rating in a report on Friday, January 4th. Ten research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $10.89.

WARNING: “Citigroup Inc. Has $35,000 Stake in MedEquities Realty Trust Inc (MRT)” was originally reported by Fairfield Current and is the property of of Fairfield Current. If you are reading this news story on another domain, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this news story can be viewed at https://www.fairfieldcurrent.com/news/2019/04/11/citigroup-inc-has-35000-stake-in-medequities-realty-trust-inc-mrt.html.

About MedEquities Realty Trust

MedEquities Realty Trust (NYSE: MRT) is a self-managed and self-administered real estate investment trust that invests in a diversified mix of healthcare properties and healthcare-related real estate debt investments. The Company’s management team has extensive industry experience in acquiring, owning, developing, financing, operating, leasing and monetizing many types of healthcare properties and portfolios.

Featured Story: Stop Order

Institutional Ownership by Quarter for MedEquities Realty Trust (NYSE:MRT)

Receive News & Ratings for MedEquities Realty Trust Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for MedEquities Realty Trust and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

BlackRock Inc. Has $31 Million Holdings in Cowen Inc (COWN)

BlackRock Inc. cut its position in Cowen Inc (NASDAQ:COWN) by 4.0% during the 4th quarter, according to the company in its most recent disclosure …

Cowen logoBlackRock Inc. cut its position in Cowen Inc (NASDAQ:COWN) by 4.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,323,853 shares of the financial services provider’s stock after selling 97,614 shares during the period. BlackRock Inc. owned about 7.97% of Cowen worth $31,001,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of COWN. QCI Asset Management Inc. NY acquired a new stake in Cowen in the fourth quarter worth $41,000. Quantamental Technologies LLC bought a new stake in shares of Cowen during the fourth quarter worth $64,000. Acadian Asset Management LLC bought a new stake in shares of Cowen during the fourth quarter worth $81,000. Trexquant Investment LP bought a new stake in shares of Cowen during the third quarter worth $212,000. Finally, MetLife Investment Advisors LLC increased its position in shares of Cowen by 55.3% during the third quarter. MetLife Investment Advisors LLC now owns 20,488 shares of the financial services provider’s stock worth $334,000 after acquiring an additional 7,292 shares in the last quarter. Institutional investors own 90.71% of the company’s stock.

Shares of COWN stock opened at $16.10 on Thursday. The company has a quick ratio of 1.14, a current ratio of 1.14 and a debt-to-equity ratio of 0.69. Cowen Inc has a 12-month low of $11.80 and a 12-month high of $17.99. The firm has a market cap of $466.25 million, a PE ratio of 6.26 and a beta of 1.40.

Cowen (NASDAQ:COWN) last issued its quarterly earnings data on Thursday, February 14th. The financial services provider reported $0.28 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.11 by $0.17. Cowen had a net margin of 4.55% and a return on equity of 10.00%. The company had revenue of $259.90 million during the quarter, compared to the consensus estimate of $193.30 million. During the same quarter in the prior year, the firm earned ($0.30) earnings per share. The firm’s revenue was up 27.1% compared to the same quarter last year.

Separately, BidaskClub raised shares of Cowen from a “sell” rating to a “hold” rating in a research report on Monday, February 4th.

ILLEGAL ACTIVITY NOTICE: This story was originally published by Fairfield Current and is the sole property of of Fairfield Current. If you are reading this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The legal version of this story can be viewed at https://www.fairfieldcurrent.com/news/2019/04/11/blackrock-inc-has-31-million-holdings-in-cowen-inc-cown.html.

Cowen Company Profile

Cowen Inc is a publicly owned asset management holding company. Through its subsidiaries, the firm provides alternative investment management, investment banking, research, and sales and trading services for its clients. It manages separate client focused portfolio through its subsidiaries. Through its subsidiaries, the firm invests in equity and fixed income markets.

Further Reading: Catch-Up Contributions

Want to see what other hedge funds are holding COWN?Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cowen Inc (NASDAQ:COWN).

Institutional Ownership by Quarter for Cowen (NASDAQ:COWN)

Receive News & Ratings for Cowen Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Cowen and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

BlackRock Inc. Has $30.63 Million Stake in Mastercraft Boat Holdings Inc (MCFT)

BlackRock Inc. lessened its position in Mastercraft Boat Holdings Inc (NASDAQ:MCFT) by 18.2% in the fourth quarter, HoldingsChannel.com reports.

Mastercraft Boat logoBlackRock Inc. lessened its position in Mastercraft Boat Holdings Inc (NASDAQ:MCFT) by 18.2% in the fourth quarter, HoldingsChannel.com reports. The fund owned 1,637,849 shares of the company’s stock after selling 363,268 shares during the period. BlackRock Inc. owned about 0.09% of Mastercraft Boat worth $30,627,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Victory Capital Management Inc. grew its position in shares of Mastercraft Boat by 4.1% in the 4th quarter. Victory Capital Management Inc. now owns 15,876 shares of the company’s stock valued at $297,000 after acquiring an additional 619 shares during the period. Teachers Advisors LLC grew its position in shares of Mastercraft Boat by 1.4% in the 3rd quarter. Teachers Advisors LLC now owns 104,405 shares of the company’s stock valued at $3,746,000 after acquiring an additional 1,419 shares during the period. Summit Global Investments grew its position in shares of Mastercraft Boat by 13.4% in the 3rd quarter. Summit Global Investments now owns 25,400 shares of the company’s stock valued at $911,000 after acquiring an additional 3,000 shares during the period. Neuberger Berman Group LLC grew its position in shares of Mastercraft Boat by 9.8% in the 3rd quarter. Neuberger Berman Group LLC now owns 42,045 shares of the company’s stock valued at $1,508,000 after acquiring an additional 3,750 shares during the period. Finally, MetLife Investment Advisors LLC grew its position in shares of Mastercraft Boat by 55.3% in the 3rd quarter. MetLife Investment Advisors LLC now owns 14,297 shares of the company’s stock valued at $513,000 after acquiring an additional 5,092 shares during the period. 90.51% of the stock is owned by institutional investors.

NASDAQ MCFT opened at $23.48 on Thursday. The company has a quick ratio of 0.46, a current ratio of 0.89 and a debt-to-equity ratio of 1.97. The stock has a market cap of $433.04 million, a PE ratio of 11.57, a P/E/G ratio of 0.59 and a beta of 1.67. Mastercraft Boat Holdings Inc has a 52-week low of $17.60 and a 52-week high of $39.50.

Mastercraft Boat (NASDAQ:MCFT) last posted its earnings results on Thursday, February 7th. The company reported $0.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.59 by $0.05. The company had revenue of $121.50 million during the quarter, compared to analysts’ expectations of $112.54 million. Mastercraft Boat had a net margin of 10.69% and a return on equity of 80.59%. Mastercraft Boat’s quarterly revenue was up 55.0% compared to the same quarter last year. During the same quarter last year, the company posted $0.42 EPS. As a group, equities research analysts expect that Mastercraft Boat Holdings Inc will post 2.69 earnings per share for the current year.

A number of research analysts have recently commented on MCFT shares. BidaskClub raised shares of Mastercraft Boat from a “hold” rating to a “buy” rating in a research report on Thursday, February 28th. ValuEngine raised shares of Mastercraft Boat from a “sell” rating to a “hold” rating in a research report on Thursday, February 7th. Zacks Investment Research downgraded shares of Mastercraft Boat from a “buy” rating to a “hold” rating in a research report on Wednesday, December 19th. Finally, Wells Fargo & Co decreased their price objective on shares of Mastercraft Boat from $41.00 to $27.00 and set an “outperform” rating for the company in a research report on Tuesday, December 18th. Four analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $38.00.

COPYRIGHT VIOLATION WARNING: “BlackRock Inc. Has $30.63 Million Stake in Mastercraft Boat Holdings Inc (MCFT)” was originally published by Highlight Press and is the sole property of of Highlight Press. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at https://highlightpress.com/2019/04/11/blackrock-inc-has-30-63-million-stake-in-mastercraft-boat-holdings-inc-mcft.html.

Mastercraft Boat Profile

MasterCraft Boat Holdings, Inc, through its subsidiaries, designs, manufactures, and markets recreational powerboats. The company operates in two segments, MasterCraft and NauticStar. It offers sport boats and outboard boats, which are used for water skiing, wakeboarding, wake surfing, and fishing, as well as general recreational boating.

Further Reading: Is it Safe to Invest in Commodities?

Want to see what other hedge funds are holding MCFT?Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mastercraft Boat Holdings Inc (NASDAQ:MCFT).

Institutional Ownership by Quarter for Mastercraft Boat (NASDAQ:MCFT)

Receive News & Ratings for Mastercraft Boat Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Mastercraft Boat and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

MetLife Investment Advisors LLC Has $3.33 Million Holdings in BIO-TECHNE Corp (TECH)

AQR Capital Management LLC grew its position in shares of BIO-TECHNE by 99.5% in the third quarter. AQR Capital Management LLC now owns …

BIO-TECHNE logoMetLife Investment Advisors LLC lowered its holdings in BIO-TECHNE Corp (NASDAQ:TECH) by 0.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 23,028 shares of the biotechnology company’s stock after selling 72 shares during the period. MetLife Investment Advisors LLC owned approximately 0.06% of BIO-TECHNE worth $3,333,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Kornitzer Capital Management Inc. KS raised its holdings in BIO-TECHNE by 114.0% during the third quarter. Kornitzer Capital Management Inc. KS now owns 278,368 shares of the biotechnology company’s stock valued at $56,818,000 after buying an additional 148,297 shares in the last quarter. Massachusetts Financial Services Co. MA grew its position in shares of BIO-TECHNE by 18.5% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 803,633 shares of the biotechnology company’s stock valued at $116,303,000 after purchasing an additional 125,665 shares during the last quarter. AQR Capital Management LLC grew its position in shares of BIO-TECHNE by 99.5% in the third quarter. AQR Capital Management LLC now owns 226,409 shares of the biotechnology company’s stock valued at $46,212,000 after purchasing an additional 112,946 shares during the last quarter. Rehmann Capital Advisory Group grew its position in shares of BIO-TECHNE by 19,957.0% in the third quarter. Rehmann Capital Advisory Group now owns 104,096 shares of the biotechnology company’s stock valued at $510,000 after purchasing an additional 103,577 shares during the last quarter. Finally, BlackRock Inc. grew its position in shares of BIO-TECHNE by 2.3% in the fourth quarter. BlackRock Inc. now owns 3,855,948 shares of the biotechnology company’s stock valued at $558,034,000 after purchasing an additional 85,590 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

NASDAQ TECH opened at $203.41 on Thursday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.31 and a current ratio of 4.35. The company has a market cap of $7.60 billion, a price-to-earnings ratio of 49.98, a P/E/G ratio of 4.49 and a beta of 1.25. BIO-TECHNE Corp has a 1-year low of $132.75 and a 1-year high of $206.04.

BIO-TECHNE (NASDAQ:TECH) last posted its earnings results on Tuesday, February 5th. The biotechnology company reported $1.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.98 by $0.08. BIO-TECHNE had a net margin of 14.02% and a return on equity of 13.90%. The company had revenue of $174.50 million during the quarter, compared to analysts’ expectations of $171.39 million. During the same quarter in the previous year, the company posted $1.02 earnings per share. BIO-TECHNE’s quarterly revenue was up 13.2% compared to the same quarter last year. On average, sell-side analysts predict that BIO-TECHNE Corp will post 3.68 EPS for the current year.

Several equities research analysts have recently issued reports on TECH shares. BidaskClub raised BIO-TECHNE from a “sell” rating to a “hold” rating in a research report on Tuesday, January 15th. Zacks Investment Research downgraded BIO-TECHNE from a “hold” rating to a “sell” rating in a research report on Wednesday, December 12th. Argus reissued a “buy” rating on shares of BIO-TECHNE in a research report on Monday, March 4th. Stephens raised BIO-TECHNE from an “equal weight” rating to an “overweight” rating and set a $180.00 target price on the stock in a research report on Monday, January 14th. Finally, ValuEngine raised BIO-TECHNE from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, February 5th. Four equities research analysts have rated the stock with a hold rating, five have issued a buy rating and two have issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $188.13.

ILLEGAL ACTIVITY WARNING: “MetLife Investment Advisors LLC Has $3.33 Million Holdings in BIO-TECHNE Corp (TECH)” was originally posted by Fairfield Current and is the sole property of of Fairfield Current. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.fairfieldcurrent.com/news/2019/04/11/bio-techne-corp-tech-shares-sold-by-metlife-investment-advisors-llc.html.

About BIO-TECHNE

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates in three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers specialized proteins, such as cytokines and growth factors, immunoassays, antibodies, and related reagents to the biotechnology research community; and in situ hybridization, media, and other cell culture products and reagents.

Further Reading: Why Invest in Dividend Achievers?

Institutional Ownership by Quarter for BIO-TECHNE (NASDAQ:TECH)

Receive News & Ratings for BIO-TECHNE Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for BIO-TECHNE and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Epizyme Inc (NASDAQ:EPZM) Shares Bought by Two Sigma Investments LP

Two Sigma Investments LP boosted its position in shares of Epizyme Inc (NASDAQ:EPZM) by 543.0% in the fourth quarter, according to the company …

Epizyme logoTwo Sigma Investments LP boosted its position in shares of Epizyme Inc (NASDAQ:EPZM) by 543.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 270,213 shares of the biopharmaceutical company’s stock after purchasing an additional 228,192 shares during the period. Two Sigma Investments LP owned about 0.34% of Epizyme worth $1,665,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of EPZM. American International Group Inc. grew its stake in shares of Epizyme by 13.0% during the fourth quarter. American International Group Inc. now owns 39,223 shares of the biopharmaceutical company’s stock worth $242,000 after buying an additional 4,513 shares during the last quarter. Quantamental Technologies LLC acquired a new position in shares of Epizyme during the fourth quarter valued at about $43,000. JGP Global Gestao de Recursos Ltda. acquired a new position in shares of Epizyme during the fourth quarter valued at about $76,000. MetLife Investment Advisors LLC raised its holdings in shares of Epizyme by 50.5% during the third quarter. MetLife Investment Advisors LLC now owns 37,738 shares of the biopharmaceutical company’s stock valued at $400,000 after purchasing an additional 12,663 shares during the period. Finally, Shell Asset Management Co. acquired a new position in shares of Epizyme during the third quarter valued at about $198,000. Institutional investors and hedge funds own 72.63% of the company’s stock.

NASDAQ EPZM traded down $0.01 on Wednesday, hitting $13.46. The stock had a trading volume of 72,735 shares, compared to its average volume of 920,656. The stock has a market capitalization of $1.22 billion, a PE ratio of -7.83 and a beta of 3.14. Epizyme Inc has a 52-week low of $5.14 and a 52-week high of $18.70.

Epizyme (NASDAQ:EPZM) last posted its quarterly earnings data on Tuesday, February 26th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.46) by $0.17. On average, analysts forecast that Epizyme Inc will post -2.18 EPS for the current fiscal year.

Several research firms have recently commented on EPZM. Zacks Investment Research downgraded shares of Epizyme from a “buy” rating to a “hold” rating in a research report on Monday, January 21st. ValuEngine raised shares of Epizyme from a “sell” rating to a “hold” rating in a research report on Thursday, January 10th. BidaskClub raised shares of Epizyme from a “hold” rating to a “buy” rating in a research report on Tuesday, January 15th. Finally, Leerink Swann raised shares of Epizyme from a “market perform” rating to an “outperform” rating and set a $12.00 price objective for the company in a research report on Monday, January 7th. Three research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $18.40.

ILLEGAL ACTIVITY NOTICE: This story was first reported by Modern Readers and is the sole property of of Modern Readers. If you are reading this story on another site, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The original version of this story can be viewed at https://www.modernreaders.com/news/2019/04/10/two-sigma-investments-lp-raises-stake-in-epizyme-inc-epzm.html.

Epizyme Company Profile

Epizyme, Inc, a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company’s lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors.

Featured Article: How does a reverse stock split work?

Institutional Ownership by Quarter for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Epizyme and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts